STAT3 and breast carcinoma: A pharmacological inhibition with the STAT3 inhibitor S3I-201 was shown to block the STAT3-G9a interaction and decrease H3K9me2 marks on the miR-200c promoter, thereby inhibiting EMT, inducing autophagy, and reducing the CSC population in breast cancer.